Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.

Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B.

J Clin Oncol. 2004 Mar 15;22(6):1045-54. Epub 2004 Feb 23.

PMID:
14981106
2.

Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers.

Domchek SM, Stopfer JE, Rebbeck TR.

J Natl Compr Canc Netw. 2006 Feb;4(2):177-82. Review.

PMID:
16451773
3.

Prophylactic oophorectomy in women at increased cancer risk.

Domchek SM, Rebbeck TR.

Curr Opin Obstet Gynecol. 2007 Feb;19(1):27-30. Review.

PMID:
17218848
4.

Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.

Finch A, Narod SA.

Maturitas. 2011 Nov;70(3):261-5. doi: 10.1016/j.maturitas.2011.08.001. Epub 2011 Sep 4. Review.

PMID:
21893388
5.

Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.

Gadducci A, Biglia N, Cosio S, Sismondi P, Genazzani AR.

Gynecol Endocrinol. 2010 Aug;26(8):568-77. doi: 10.3109/09513590.2010.487609. Review.

PMID:
20632911
6.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
7.

Genetic susceptibility testing and prophylactic oophorectomy.

Berchuck A, Carney ME, Futreal PA.

Eur J Obstet Gynecol Reprod Biol. 1999 Feb;82(2):159-64. Review.

PMID:
10206409
8.

Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer.

Berek JS, Chalas E, Edelson M, Moore DH, Burke WM, Cliby WA, Berchuck A; Society of Gynecologic Oncologists Clinical Practice Committee.

Obstet Gynecol. 2010 Sep;116(3):733-43. doi: 10.1097/AOG.0b013e3181ec5fc1. Review.

PMID:
20733460
9.

Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention.

S√łgaard M, Kjaer SK, Gayther S.

Acta Obstet Gynecol Scand. 2006;85(1):93-105. Review.

PMID:
16521688
10.

The role of estrogens in BRCA1/2 mutation carriers: reflections on the past, issues for the future.

de Carvalho M, Jenkins J, Nehrebecky M, Lahl L.

Cancer Nurs. 2003 Dec;26(6):421-30. Review.

PMID:
15022973
11.

BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.

Brunsvold AN, Wung SF, Merkle CJ.

J Am Acad Nurse Pract. 2005 Dec;17(12):518-26. Review.

PMID:
16293160
12.

Systematic review of management options for women with a hereditary predisposition to ovarian cancer.

Rosen B, Kwon J, Fung Kee Fung M, Gagliardi A, Chambers A; Cancer Care Ontario's Practice Guidelines Initiative Gynecology Cancer Disease Site Group.

Gynecol Oncol. 2004 May;93(2):280-6. Review.

PMID:
15099934
13.

Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.

Roukos DH, Briasoulis E.

Nat Clin Pract Oncol. 2007 Oct;4(10):578-90. Review.

PMID:
17898808
14.

Prophylactic mastectomy: why and when?

von Smitten K.

J Br Menopause Soc. 2003 Dec;9(4):151-5. Review.

PMID:
15107257
15.

Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations.

Olopade OI, Artioli G.

Breast J. 2004 Jan-Feb;10 Suppl 1:S5-9. Review.

PMID:
14984481
16.

Estimated gains in life expectancy with use of postmenopausal estrogen therapy: a decision analysis.

Zubialde JP, Lawler F, Clemenson N.

J Fam Pract. 1993 Mar;36(3):271-80. Review.

PMID:
8454973
17.

Hereditary ovarian cancer--assessing risk and prevention strategies.

Pavelka JC, Li AJ, Karlan BY.

Obstet Gynecol Clin North Am. 2007 Dec;34(4):651-65, vii-viii. Review.

PMID:
18061862
18.
19.

Hormone therapy in oophorectomized BRCA1/2 mutation carriers.

Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, Panici PB.

Menopause. 2014 Jul;21(7):763-8. doi: 10.1097/GME.0000000000000126. Review.

PMID:
24253485
20.

[Chemoprevention and prophylactic surgery in ovarian carcinoma].

Deffieux X, Touboul C, Uzan C, Faivre E, Frydman R, Fernandez H, Morice P.

J Gynecol Obstet Biol Reprod (Paris). 2007 Dec;36(8):756-63. Epub 2007 Aug 23. Review. French.

Supplemental Content

Support Center